Lumos Pharma, Inc.
(NASDAQ GM: LUMO)
Rigrodsky Law, P.A. is investigating Lumos Pharma, Inc. (“Lumos”) regarding possible breaches of fiduciary duties and other violations of law related to Lumos’s agreement to be acquired by Double Point Ventures LLC. Under the terms of the agreement, Lumos shareholders will receive $4.25 per share in cash.